Duncan Smyth

Duncan Smyth

Auto-generated profile, based on publicly available information

Duncan Smyth

Neuromuscular Diseases, UCL, London, UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2023 in Practical Neurology
Verified
Journal Article
Closed access
PDF file
DSDuncan Smyth
Duncan Smyth
CKCaroline Kramarz
Caroline Kramarz
ACAisling S Carr
Aisling S Carr
ARAlexander M Rossor
Alexander M Rossor
MLMichael P Lunn
Michael P Lunn
Toxic neuropathies result from exogenous substances damaging the peripheral nerves. There are numerous causes, including prescribed and recreational drugs, heavy metals, industrial agents and biological toxins. Timely recognition of these neuropathies gives better outcomes, as they usually improve or stabilise once the toxin is removed. Most toxic neuropathies are axonal, length-dependent and sensory predominant, although some have significant motor involvement or can present acutely or subacutely. Here, we outline our clinical approach and discuss the major causes of toxic neuropathy, while emphasising the clinical and neurophysiological features and the neuropathy phenotype. We also include an update on newer medications that can cause neuropathy, including immune checkpoint inhibitors and BRAF/MEK inhibitors.

9 May 2009 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
DSD. Smyth
D. Smyth
RRR. Rehman
R. Rehman
KRK. Remund
K. Remund
JEJ. Egan
J. Egan

16 July 2019 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
DSDuncan Smyth
Duncan Smyth
SMStuart Mossman
Stuart Mossman
MWMark Weatherall
Mark Weatherall
EJEvan Jolliffe
Evan Jolliffe
PJPurwa Joshi
Purwa Joshi
ESErich Schneider
Erich Schneider
Objectives: To determine the incidence of gentamicin vestibulotoxicity with current dosing regimens, and to evaluate the feasibility of routine video-oculography on all patients given gentamicin. Materials and methods: In this prospective incidence study serial horizontal vestibulo-ocular reflex (HVOR) gain measurements were recorded using video-oculography on adult inpatients receiving intravenous gentamicin. The primary outcome was the proportion of patients developing impairment of their HVOR gain. Results: After exclusions, 42 patients were included in the analysis. Three patients (7.1%) developed asymptomatic vestibulotoxicity, exact 95% confidence interval 1.5–19.5%. In two of these patients the deficit resolved within several hours. No patients developed symptomatic vestibulotoxicity. There was no evidence for a generalised reduction in group HVOR gain with time. HVOR gain was not associated with total gentamicin dose, dynamic visual acuity or subjective imbalance. Conclusions and significance: Gentamicin may cause reversible, asymptomatic vestibulotoxicity. Video-oculography may be useful to monitor for vestibulotoxicity in patients treated with gentamcin; however, testing all patients routinely may be challenging.

5 January 2026 in BMJ Neurology Open
Verified
Journal Article
Open access
DSDuncan Smyth
Duncan Smyth
RKRyan Y S Keh
Ryan Y S Keh
SKStephen Keddie
Stephen Keddie
MCMichael Chou
Michael Chou
MHMelanie Hart
Melanie Hart
MLMichael P Lunn
Michael P Lunn
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a potentially disabling complication of the neurotoxic chemotherapies; however, its occurrence is often unpredictable. We aimed to determine whether serum levels of neurofilament light chain (sNfL) could predict the onset and severity of CIPN, and whether sNfL levels were associated with other clinical factors in people with cancer. Methods: Adult patients (>18 years) prescribed at least four cycles of oxaliplatin, cisplatin, docetaxel or paclitaxel were clinically assessed and had blood taken for sNfL analysis at baseline and prior to each cycle. Peak sNfL was compared with clinical characteristics and Total Neuropathy Score-Clinical version (TNSc), National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, V.4.03) and CIPN-Rasch-built Overall Disability Scale (CIPN-RODS). Individual patient trends in sNfL and TNSc were examined. Results: 42 patients completed the study, with 36 receiving platinum agents and 6 receiving taxanes. Peak sNfL was higher with taxanes than with platinum agents (129.9 vs 31.0 pg/mL; p<0.0001). Higher peak sNfL was not associated with final TNSc, CTCAE or CIPN-RODS in patients receiving platinum agents. Using age-adjusted NfL z-scores, peak sNfL was associated with CIPN-RODS (rs=−0.45; p=0.012) and was higher in patients with a final CTCAE Grade of 2 compared with Grades 0–1 (p=0.015) but was not associated with final TNSc (rs=+0.37, p=0.050). In patients receiving platinum agents, higher peak sNfL was associated with death within 6 months of study entry (p=0.020). sNfL rose in conjunction with the increase in TNSc but did not precede clinical symptoms/signs of neuropathy in most patients. Conclusion: Taxanes cause greater and sharper sNfL rises than platinum agents. Age-adjusted sNfL associates with neuropathy severity in platinum-treated patients; however, in most patients it is unable to detect early axonal damage before this is detectable with clinical examination.


4 October 2018 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
DSDuncan Smyth
Duncan Smyth
MWMark Weatherall
Mark Weatherall
IRIan Rosemergy
Ian Rosemergy
KWKelvin Woon
Kelvin Woon
JLJeremy Lanford
Jeremy Lanford